1	The Phenome-wide Consequences of Anorexia Nervosa Genes					
2	Jessica S. Johnson, MPH <sup>1,2</sup> , Alanna C. Cote <sup>1,2</sup> , Amanda Dobbyn, PhD <sup>1-3</sup> , Laura G. Sloofman, MS <sup>4</sup> , Jiayi					
3	Xu, PhD <sup>1,2</sup> , Liam Cotter <sup>1,2</sup> , Alexander W. Charney, MD, PhD <sup>1-3,5,6</sup> , Eating Disorders Working Group of the					
4	Psychiatric Genomics Consortium <sup>*</sup> , Jennifer Jordan, PhD <sup>7</sup> , Martin Kennedy, PhD <sup>7</sup> , Mikael Landén, MD,					
5	PhD <sup>8,9</sup> , Sarah L Maguire, PhD <sup>10</sup> , Nicholas G Martin, PhD <sup>11</sup> , Preben Bo Mortensen, MD, DMSc <sup>12</sup> , Cynthia					
6	M. Bulik, PhD <sup>9,13,14</sup> , Laura M. Huckins, PhD <sup>1-6†</sup>					
7						
8	<sup>1</sup> Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, NY					
9	10029, USA					
10	<sup>2</sup> Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029,					
11	USA					
12	<sup>3</sup> Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York,					
13	NY 10029, USA					
14	<sup>4</sup> Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New					
15	York, NY 10029, USA					
16	<sup>5</sup> Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA					
17	<sup>6</sup> Mental Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans					
18	Affairs Medical Center, Bronx, NY 14068, USA					
19	<sup>7</sup> University of Otago, Department of Psychological Medicine, Christchurch School of Medicine & Health					
20	Sciences, 2 Riccarton Avenue, PO Box 4345, 8140 Christchurch, New Zealand					
21	<sup>8</sup> Gothenburg University, Box 100, SE-405 30 Gothenburg, Sweden					
22	<sup>9</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden					
23	<sup>10</sup> School of Medicine, InsideOut Institute, Sydney, New South Wales, 2006, Australia					
24	<sup>11</sup> QIMR Berghofer Medical Research Institute, Locked Bag 2000, Royal Brisbane Hospital QLD 4029,					
25	Australia					
26	<sup>12</sup> Aarhus University, Norde Ringgade 1, 8000 Aarhus, Denmark					
27	<sup>13</sup> Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA					
28	<sup>14</sup> Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA					

<sup>\*</sup> Full list of PGC-ED working group authors is available in the supplementary materials.

<sup>&</sup>lt;sup>†</sup> Corresponding author: Dr. Laura M. Huckins, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., 3<sup>rd</sup> Floor, Room L3-70i, New York, NY 10029; laura.huckins@mssm.edu, (212) 659-1613.

#### 29 ABSTRACT

31	Anorexia nervosa (AN) is a psychiatric disorder with complex etiology, with a significant portion of disease
32	risk imparted by genetics. Traditional GWAS studies produce principal evidence for the association of
33	genetic variants with disease, and provide a jumping-off point for downstream functional analyses.
34	Transcriptomic imputation (TI) allows for the translation of SNPs into regulatory mechanisms, which can
35	then be used to assess the functional outcome of genetically regulated gene expression (GReX) in a
36	more broad setting through the use of phenome-wide association studies (PheWAS) in large and diverse
37	clinical biobank populations with electronic health record (EHR) phenotypes. Here, we applied TI using S-
38	PrediXcan to translate the most recent PGC-ED AN GWAS findings into AN-GReX. For significant genes,
39	we imputed AN-GReX in the Mount Sinai BioMe™ Biobank and performed PheWAS on over 2000 clinical
40	outcomes to test the clinical consequences of aberrant expression of these genes. We performed a
41	secondary analysis to assess the impact of BMI on AN-GReX clinical associations.
42	
43	Our S-PrediXcan analysis identified 47 genes associated with AN, including what is, to our knowledge,
44	the first genetic association of AN with the Major Histocompatibility Complex (MHC). AN-GReX was
45	associated with autoimmune, anthropometric, metabolic, psychiatric and gastrointestinal diagnoses in our
46	biobank cohort, as well as measures of anthropometry, substance use, and pain score. Our analyses
47	reveal that AN-GReX associations with measures of weight and substance use are modified by BMI, and
48	indicate potential avenues of functional mechanism to investigate further.

- 49
- 50

#### 51 INTRODUCTION

53	Anorexia nervosa (AN) is a severe eating disorder characterized by extreme low body weight and fear of
54	gaining weight, and is often accompanied by compensatory behaviors to lose weight such as dietary
55	restriction, purging, and higher than average physical activity(1). With a lifetime prevalence of 0.9-4%, AN
56	has high mortality, with few effective treatments and an increased risk of suicide(2-4). Clinical and
57	epidemiological studies have shown higher risk of other psychiatric disorders such as OCD, anxiety, and
58	major depression in individuals with AN(3,5), and higher risk of substance use disorders in AN subtypes
59	(6), as well as higher risk of metabolic and autoimmune disorders such as type 1 diabetes(7,8). Twin
60	studies have established the heritability of AN to be between 50 to 60%, indicating a considerable
61	contribution of genetic factors to AN disease liability(9,10)
62	
63	Both metabolic and psychiatric factors contribute to anorexia nervosa. Epidemiological studies indicate
64	high rates of psychiatric comorbidity, particularly with depression, anxiety disorders, and OCD(5), and
65	many of these disorders share substantial symptomatology and environmental risk factors(11). Evidence
66	is mounting that AN may lie at the extreme of a BMI spectrum, with obesity lying at the opposite end, and
67	that AN may be a disorder of "fundamental metabolic dysregulation"(2). In line with this hypothesis,
68	individuals with AN are able to reach and maintain incredibly low body weight, and often revert to this
69	weight even after re-nourishment treatment, possibly indicating a fundamentally low BMI biological
70	settling point(12,13). Additionally, individuals with AN have been shown to have lower concentrations of
71	leptin, a hormone involved in regulation of body weight and other metabolic processes(13–16).
72	Microbiome studies have revealed abnormal microflora in the gut of AN patients(17), and evidence from
73	many studies have pointed to a possible brain-gut etiology of AN(9,18–20).
74	
75	Genetic studies of AN have provided further evidence of both psychiatric and metabolic etiology. The
76	largest AN GWAS to date (N <sub>Cases</sub> =16992) uncovered eight loci associated with AN risk(9), and determined
77	SNP-based heritability (h <sup>2</sup> <sub>SNP</sub> ) of 11-17%, similar to other psychiatric disorders, indicating that common
78	variants contribute to polygenic risk of AN. In addition, genetic correlations demonstrate significant

overlap with other psychiatric disorders, including schizophrenia(9,21), MDD(9), OCD(9), alcohol use
disorder(22) and anxiety disorders(9), as well as physical activity(9,23), indicating shared genetic
variation between these traits. Significant negative genetic correlation between AN and anthropometric
and metabolic traits, such as BMI(9,21,23), fat mass(9,21,23), obesity(9), type 2 diabetes(9), insulin
resistance(9,21), fasting insulin(9,21) and leptin(9) have also been observed, further indicating metabolic
components to AN disease risk. One study of AN polygenic risk scores (PRS) has indicated additional
genetic associations of AN risk variants with anthropometric, behavioral, and psychiatric traits(24).

86

87 Traditional observational genetic studies provide substantial data for factors contributing to risk of a 88 particular disease, but may not capture the genetic factors that are specifically contributing to 89 subthreshold or prodromal disease states. Electronic Health Records (EHR) contain information about an 90 individual's health history such as diagnoses, medications, laboratory tests, vital signs, and family medical 91 history, and can be utilized for scalable disease research. The vast amounts of data from the EHR can be 92 queried to provide an understanding of the clinical spectrum of disease and disease progression across 93 the lifetime of the patient. The initiation of biobanks to collect biological specimens from large numbers of 94 patients within a healthcare system allows us to connect massive amounts of phenotype data from the 95 EHR to genetic data. A phenome-wide association study or PheWAS is an effective method of querying 96 the EHR to look for the associations of a trait of interest with the clinical phenome (25–27). Previous 97 studies have demonstrated the efficacy of PheWAS methods in determining clinical outcomes associated 98 with genomic disease risk variants, and have replicated associations from GWASs of strictly defined 99 disease traits, including psychiatric disorders(28-30). Exploring the phenotypic associations with AN 100 genetic architecture has the potential to clarify how some of these GWAS variants functionally contribute 101 to AN disease risk, symptomatology, and clinical presentation.

102

Transcriptomic imputation (TI) approaches leverage expression quantitative trait loci (eQTLs) derived from large, well-curated gene expression datasets (for example, the Genotype-Tissue Expression project (GTEx)(31), CommonMind Consortium (CMC)(32), and Depression Genes and Networks (DGN)(33)) in order to derive gene expression predictor models. These models may be applied to predict genetically

107	regulated gene expression (GReX) in large genotyped cohorts, without the need to collect tissue samples
108	or RNA(19,34–36). Here, we explored the association between AN-associated GReX and the clinical
109	phenome. We performed transcriptomic imputation using S-PrediXcan on the most recent PGC-ED AN
110	GWAS to first find GReX associated with AN, and then tested for clinical associations of these genes with
111	structured EHR-encoded phenotypes using PheWAS. Given the relationship of AN with BMI, we further
112	investigated the effect of BMI on the GReX-phenotype associations by stratifying biobank individuals
113	based on sex- and ancestry-adjusted categories of low, mid, and high BMI. Understanding the clinical
114	consequences of aberrant gene expression across the phenome may clarify the biological mechanisms of
115	clinically relevant AN GWAS risk variants.
116	
117	
118	
119	
120	
121	
122	
123	

#### 125 **METHODS**

126

#### 127 AN GENELIST and TRANSCRIPTOMIC IMPUTATION

- 128 We performed transcriptomic imputation using S-PrediXcan(35) on the largest available summary
- 129 statistics of Anorexia Nervosa (AN) (16992 AN cases and 55525 controls) downloaded from the
- 130 Psychiatric Genomics Consortium (PGC) website(9). We tested for association of genetically-regulated
- 131 gene expression (GReX) using available GTEx, CMC and DGN predictor models(34-36) for a total of 50
- 132 different tissues with AN case-control status. We established two thresholds for significance; first,
- 133 correcting for all genes tested within each tissue (ptissue, values shown in **Table S1**, and second,
- 134 correcting for all tissues and genes tested ( $p_{\text{honferron}}=3.75 \times 10^{-8}$ ).
- 135

#### 136 Bio*Me*<sup>™</sup>

137 The BioMe<sup>TM</sup> Biobank at the Icahn School of Medicine at Mount Sinai includes genotype and EHR data 138

from 31704 individuals recruited from the general patient population of the Mount Sinai healthcare

139 system. Individuals were genotyped on the Illumina Global Screening Array (GSA), an array designed for

140 multi-ethnic populations. The BioMe<sup>TM</sup> population is very diverse, with the proportion of major ancestral

141 population groups representative of the diversity of New York City and Mount Sinai's patient population:

142 Hispanic (HA, 35%), European (EA, 34%), African (AA, 25%), East Asian (ESA, 3%), South Asian (SAS,

143 2%), and Native American (NA, 0.3%) (Full Bio*Me<sup>TM</sup>* demographics are shown in **Table 1**). Quality control

144 and imputation of the genotyping data for  $BioMe^{TM}$  is described in elsewhere(28).

145

146 Ancestry for BioMe<sup>TM</sup> was initially assigned from self-reported values into six ancestral groupings: African 147 (AA), European (EA), Hispanic (HA), East Asian (ESA), Native American (NA), and O (Other). We plotted 148 the first two principal components from the genotyping to confirm ancestral grouping. For individuals not 149 clearly falling in an ancestral group, and for those designated "Other", we merged genotype information 150 with phase 3 of 1000Genomes and reran the principal components analysis (PCA) using PLINK(37,38) in 151 order to assign individuals to 1000Genomes super-populations. From this we were able to assign 152 individuals to one of six ancestral groups: African (AA), European (EA), East Asian (ESA), Hispanic (HA),

Native American (NA), and South Asian (SAS). A total of 119 samples that could not be grouped were
 removed, leaving 31585 individuals for analysis.

155

#### 156 **PheWAS**

157 We calculated GReX for all *p*<sub>tissue</sub> significant genes across GTEx(31), DGN(33), and CMC(32,39) tissues

- 158 (N=50) in Bio*Me<sup>TM</sup>* individuals using PrediXcan-2(34,35) software, and performed a phenome-wide
- association (PheWAS) analysis. Logistic regression between the calculated AN-GReX and phecodes was
- 160 performed using the PheWAS R package(40), adjusting for age, biological sex, and the first five
- 161 genotype-derived principal components. PheWAS were run per Bio*Me<sup>TM</sup>* ancestry cohort of (N<sub>Ancestry</sub>=6)
- and results meta-analyzed using an inverse-variance based approach in METAL(41). Due to the nature of
- 163 EHR data, sample sizes can vary greatly depending on the phenotype, which can, in turn, affect our
- ability to detect associations. We believe our study is sufficiently powered given results from a previous
- study(42) that used simulations of MAF, penetrance and sample number parameters to estimate power
- 166 for pheWAS studies.
- 167

#### 168 Encounter Diagnosis

Current diagnoses for each individual were recorded at each visit using the International Classification of Disease (ICD) coding system and recorded as "Encounter Diagnosis". Phecodes were assigned from Encounter Diagnosis information by grouping ICD-9 and ICD-10 diagnostic codes(43). Individuals with at least two counts of a particular diagnostic code were considered "cases", those with zero counts were marked as "controls", and those with only one count were set to missing. After QC, there were a total of 2178 unique Encounter Diagnosis codes and 1093 unique phecodes in the dataset.

175

For both encounter diagnoses and phecodes, we required at least 10 occurrences of each phenotype within each population group for inclusion in the analysis, and an overall effective sample size  $N_{eff} > 100$  (Equation 1).

$$N_{eff} = \frac{4}{(1/N_{\text{Cases}}) + (1/N_{\text{Controls}})}$$

179 Equation 1: Effective sample size (N<sub>eff</sub>)

181	Due to	Due to the high correlation between Encounter Diagnosis and phecode files, we combined all results from				
182	both PheWAS and performed an FDR correction in R to determine overall significant associations with					
183	diagnostic phenotypes. Significant associations were set at an FDR-corrected p threshold of 0.05.					
184						
185	Bio <i>M</i> e	-R Structured Phenotype Database (BRSPD) PheWAS				
186	In addi	tion to diagnosis code data, we also had access to other types of EHR-derived data that included				
187	informa	ation on allergy status, vital signs (weight, height, blood pressure, pulse, pulse oximetry,				
188	respira	tions, and temperature), family history, personal history, medication use, obstetrics and				
189	gyneco	ology outcomes (OB/GYN), and other social and behavioral traits. This information derived from the				
190	EHR w	as collected into files under the heading BRSPD or BioMe-R Structured Phenotype Database.				
191	Summa	aries and descriptive statistics of all of the BRSPD phenotypes can be found in Supplementary				
192	Metho	ds. For all BRSPD traits, we required at least ten cases in each ancestry group, and a total				
193	N <sub>eff</sub> >100 for inclusion in our analysis.					
194						
195	Pheno	type QC and Analysis for Continuous Traits				
196	We plo	tted the distribution of continuous traits across the cohort, and removed implausible or impossible				
197	values	(likely due to errors in entry; for example, height listed as 1745 inches). Continuous traits were				
198	then ar	nalyzed as follows:				
199	1.	Height (cm): mean measure per individual.				
200	2.	Weight (kg): (i) highest recorded weight, (ii) lowest recorded weight, (iii) weight change over time.				
201		Weight change over time was calculated by taking the difference between the highest and lowest				
202		recorded weights, divided by the number of years between those two measures.				
203	3.	Pain scores were self-reported on a 1 to 10 scale and assessed for 25 different body locations.				
204		First, we tested pain score regardless of location, using three measures: (i) highest ever pain				
205		score, (ii) mean pain score, (iii) total pain score (sum), to encompass both acute and chronic pain				
206		conditions. We then repeated this analysis to each reported pain location, with the same three				
207		measures.				

208	4. Measures of alcohol, tobacco, and illicit drug use were categorized as follows: alcohol- ounces					
209	(oz) per day; tobacco- (i) packs per day and (ii) years used; illicit drug use- frequency of use.					
210	5. Vital signs (blood pressure, pulse, pulse oximetry, respiration, temperature (Celsius)) were					
211	analyzed using (i) highest ever value, (ii) lowest ever value, (iii) mean, (iv) variance per individual.					
212						
213	Categorical Traits					
214	Categorical traits were converted to binary TRUE/FALSE values (phenotypes included are shown in					
215	Supplemental Information). For allergy and medication phenotypes, we collapsed and combined data					
216	on equivalent root components and/or active ingredients (e.g., allergies for the antibiotic Vancomycin					
217	were coded as "VANCOMYCIN", "VANCOMYCIN HCL", "VANCOMYCIN IN D5W", "VANCOMYCIN IN					
218	0.9% SODIUM CL", "VANCOMYCIN IN DEXTROSE ISO-OSM", and "VANCOMYCIN (BULK)"), removed					
219	extraneous symbols and corrected typing errors. A full account of QC steps is documented in the					
220	Supplementary Methods.					
221						
222	STRATIFICATION BY BMI					
223	Given the nature of AN symptomology and association with weight phenotypes, we tested whether AN-					
224	GReX associations varied based on BMI. We stratified BioMe <sup>™</sup> individuals into three main BMI					
225	categories, defined based on ancestry- and sex-specific BMI distributions within our data (Figures S1					
226	and S2; Tables S2 and S3). BMI values used for these analyses were measured at intake into Bio <i>Me</i> <sup>™</sup> .					
227	We categorized individuals with BMI within the 1 <sup>st</sup> quartile as "Low" BMI; those above the 3 <sup>rd</sup> quartile as					
228	"High" BMI, and those falling between the 1 <sup>st</sup> and 3 <sup>rd</sup> quartiles as "Mid" BMI ( <b>Figure S1</b> ). We then					

repeated our analysis in these three groups for all significant associations from our full analysis.

#### 230 **Testing for hidden case contamination**

231 It is possible that some of the clinical associations within our study stem from undiagnosed ED- and AN-232 cases, rather than a direct effect of gene expression on phenomic expression. We term this "diagnostic 233 contamination". To test whether this effect may drive the associations we observe, we simulated the 234 effects of diagnostic contamination occurring at rate p within our biobank sample, with effect  $\beta$  on GReX. 235 236 Full derivations and simulations are shown in our Supplementary Material; briefly, we derive the 237 expression among controls, and cases contaminated at rate p; the difference in expression between the 238 two groups; the expected variance among cases, and pooled across all samples, and the expected 239 statistical significance (T-score, and p-value). Next, we simulated gene expression distributions for (i) 240 1000 cases and 1000 controls; (ii) 1000 cases and 10000 controls; (iii) 1000 cases and 30000 controls; 241 each for a range of p (0.1%, 0.5%, 1%, 2%, 5%, 10%, 20%, 30%, 40%, 50%) and  $\beta$  (1/10, 1/5,  $\frac{1}{4}$ , 1/3,  $\frac{1}{2}$ , 242 1, 2,3,4,5,10) values. We repeated our simulations 10000 times at each case-control proportion-  $p-\beta$ 243 combination, and demonstrated that our formulae accurately estimate the desired values (Figure S3). 244 245 Next, in order to test whether diagnostic contamination may account for the associations observed within 246 our PheWAS, we calculated the expected impact of diagnostic contamination for two genes (NCKIPSD-247 Aorta: SEMA3F-Spinal Cord) with the largest effect sizes  $\beta$  observed in our S-PrediXcan analysis, under 248 two scenarios: 249 1. Diagnostic contamination occurs among our cases only, assuming the normal population rate for 250 AN: 0.9% among women; 0.3% among men. 251 2. Contamination occurs at significantly higher levels than might be expected in the population 252 (1.2%, 3%, 6%), and all of these samples fall into our case category. 253 254 For each scenario, we repeated our calculation using 500 and 1000 cases, matched with 1000, 5000, and 255 30000 controls.

#### 257 **RESULTS**

258

### 259 S-PrediXcan identifies gene-tissue associations with AN

260 We applied S-PrediXcan to PGC-AN GWAS summary statistics, and identified 47 genes across 12 loci, 261 two loci on chromosomes 2 and 3 that reached experiment-wide significance ( $p < 3.75 \times 10^{-8}$ ; Figure 1, 262 Table 2, Table S4), and another 10 loci that reached tissue-specific significance (Each tissue type has its 263 own p value threshold of significance; Figure 1, Table 2, Table S4). These 12 loci encompass 218 gene-264 tissue associations (which may include the same gene associated across multiple tissues). The most 265 significant peak on chromosome 3 includes 29 genes with significant associations with AN; this region of 266 the genome overlaps with a GWAS peak for inflammatory bowel disease (IBD)(44), Crohn's disease, and 267 ulcerative colitis. Many of the AN-associated genes within this peak have been found to be associated 268 with IBD. Genes included in our AN GReX gene set have been previously associated not only with IBD, 269 but with other psychiatric traits such as schizophrenia (ARNTL, CLIC1), depression and/or depressive 270 symptoms (C3orf62, CCDC36, CLIC1, DAG1, GPX1, MST1R), autism (CLIC1), and substance use 271 (RBM5, RBM6), as well as anthropometric measures such as BMI, waist-hip ratio, and lean body mass 272 (Table S5). Of these genes, CLIC1 lies within the major histocompatibility complex (MHC), a large region 273 on chromosome 6 that includes genes that code for components of the adaptive immune system (Tibial 274 nerve-CLIC1, p=1.47 x 10<sup>-6</sup>). To our knowledge, this is the first genetic association for AN within the MHC 275 region.

276

### 277 AN-GREX is associated with anthropometric measures

We tested whether GReX of AN-associated genes was associated with anthropometric phenotypes in our Bio $Me^{TM}$  biobank (**Table 3**). In the overall cohort, upregulation of MHC-gene *CLIC1* was associated with lowest recorded weight (Spleen-*CLIC1*, p=6.63 x 10<sup>-4</sup>; Breast Mammary tissue-*CLIC1*, p=4.18 x 10<sup>-4</sup>) and mean height (Subcutaneous Adipose-*CLIC1*, p=1.39 x 10<sup>-5</sup>; **Table S6**). Downregulation of multiple genes, *ARIH2*, *NCKIPSD*, *NDUFAF3*, *NICN1*, *P4HTM*, *RNF123*, *SLC26A10*, was associated with decreased measures of weight change over time in the overall cohort (p<9.86 x 10<sup>-4</sup>)(**Table 3**, **Figure S4**). Upregulation of *WDR6* was associated with increased measures of weight change over time (p<9.81 x 10<sup>-5</sup>)

<sup>4</sup>)(**Table 3, Figure S4**). *CTNNB1*, *GPR75* and *LINC00324* GReX was associated with mean height in Bio*Me*<sup>TM</sup> (p<6.51 x 10<sup>-4</sup>)(**Table S6**).

287

#### 288 Patient BMI mediates AN-GREX-PheWAS associations

289 Given the relationship of AN with BMI, we performed a secondary analysis to assess the effect of BMI on 290 the association between AN-GReX and anthropometric phenotypes. Specifically we wanted to look at 291 whether our AN-GReX-phenotype associations in individuals of High and Low BMI were still present 292 when BMI was within a normal range. We split the BioMe<sup>™</sup> cohort into three groups: High, Mid, and Low 293 BMI (adjusted for ancestry and sex; see **Methods** and **Supplementary Information** for more details), 294 and re-ran our PheWAS within these groups. Indeed, our AN-GReX anthropometry associations (with 295 highest recorded weight, lowest recorded weight, and weight change over time) varied according to the 296 BMI group tested (Figure 2, Table 3). The association between CLIC1-GReX and highest and lowest 297 recorded weight measures was strongest in individuals of High BMI compared with the other BMI groups 298 (Figure 2, Table 3). Likewise, for multiple genes, associations between AN-GReX and weight change 299 over time differed markedly in the High BMI group (Table 3, Figure S5).

300

#### 301 **AN-GREX** is associated with autoimmune and autoinflammatory diseases

302 At a false discovery rate (FDR) p<0.05, we found 17 FDR-significant gene-tissue associations with four 303 Phecode- and Encounter Diagnosis phenotypes: type I diabetes, celiac disease, peptic ulcer, and 304 unspecified immunodeficiency (Figure 3). Upregulation of CLIC1 in spleen was associated with two 305 autoimmune/autoinflammatory phenotypes in the overall BioMe<sup>™</sup> cohort: celiac disease and type I 306 diabetes (p=1.30 x 10<sup>-11</sup>, p=5.08 x 10<sup>-20</sup>, respectively) (Tables S7 and S8). Downregulation of SLC26A6 307 was associated with the phenotype "peptic ulcer, site unspecified" in the overall cohort (Liver-SLC26A6, 308 p=8.38 x 10<sup>-8</sup>; Skeletal muscle-*SLC26A6*, p=1.71 x 10<sup>-7</sup>; Thyroid-*SLC26A6*, p=7.16 x 10<sup>-8</sup>). 309 Downregulation of PFKFB4 was associated with ICD10 code D84.9, "immunodeficiency, unspecified" 310 (Skin not sun exposed-*PFKFB4*, p=1.34 x 10<sup>-7</sup>). We stratified our cohort by BMI (see **Methods**) to assess whether BMI was modifying the association of AN-GReX with Encounter Diagnosis and phecodes. We 311 312 saw significant associations of AN-GReX phecodes within our Mid BMI group; however, when plotted

across the BMI groups, there was no notable difference in the magnitude and direction of effect of AN-

314 GReX on either Encounter Diagnosis or phecodes across the BMI groups (Figures S6 and S7). Within

- individuals with Mid BMI, upregulation of *CLIC1* was similarly associated with type 1 diabetes (Mid-
- 316 Subcutaneous adipose, Mid-Breast Mammary tissue, Mid-Spleen-*CLIC1*, p<1.96 x 10<sup>-8</sup>).
- 317

## 318 AN-GREX is associated with tobacco, alcohol, and illicit drug use

319 Multiple AN genes were associated with both categorical and continuous measures of tobacco use (Table 320 S9, Figure S8). APEH, CCDC36, DALRD3, GPX1, LINC00324, NICN1, and P4HTM were associated 321 with years used/smoked of tobacco in the overall Bio $Me^{TM}$  cohort (p<4.97 x 10<sup>-4</sup>, Table S9) and 322 upregulation of *MGMT* was associated with being a smoker (Heart Atrial Appendage-*MGMT*, p=8.87 x 10<sup>-</sup> 323 <sup>5</sup>; Putamen basal ganglia-*MGMT*,  $p=1.09 \times 10^{-4}$ ). Again, we note mediating effects of patient BMI category 324 on the association between AN-GReX and smoking phenotypes. Among the Mid and High BMI groups, 325 different genes were associated with both continuous and categorical measures of tobacco use (Table 326 **S9**, Figure S8), including years of tobacco use, tobacco cigarette packs per day, and smoking every day. 327 In addition to tobacco use measures, we see an association between AN genes and tobacco use related 328 ICD codes. Downregulation of LINC00324 in Low BMI individuals was associated with ICD10 diagnosis 329 code F17.210 "Nicotine dependence, cigarettes, uncomplicated" (Low-Cells EBV-tranformed-LINC00324, 330  $p=3.03 \times 10^{-5}$ ).

331

Downregulation of *MGMT* was associated with decreased alcohol use (ounces per week) in individuals in the Mid-BMI group (p<9.75 x  $10^{-4}$ ; **Figure S8**). In individuals of Low BMI, downregulation of *GPR75* and *GPX1*, and upregulation of *NICN1* were associated with decreased and increased continuous measures of illicit drug use frequency respectively (Liver-*GPR75*, p=3.34 x  $10^{-4}$ ; Nucleus accumbens-*GPX1*, p=2.04 x  $10^{-4}$ ; Testis-*NICN1*, p=3.34 x  $10^{-4}$ ; **Figure S8**).

337

#### 338 AN-GREX is associated with measures of pain score and pain location

We tested for association between AN-GReX and three sets of pain score measures: (1) pain location, (2)

pain score overall, (3) pain score by body location. AN-GReX was associated with multiple measures of

pain score measurement and location across all BMI groups (**Table S10**). Most significantly, upregulation of *TNFSF12* was associated with total knee pain score (sum) in individuals with High BMI (High-Brain Substantia nigra-*TNFSF12*, p=1.50 x  $10^{-3211}$ ). Downregulation of *TNFSF12* was associated with total abdomen pain score (sum) in individuals with Low BMI (Low-Brain Substantia nigra-*TNFSF12*, p=3.93 x

- $345 \quad 10^{-58}$ ) (**Table S10**).
- 346

347 When looking at pain location irrespective of pain score, upregulation of *TUSC2* in the overall cohort is

348 associated with presence of knee pain (Pancreas-*TUSC2*, p=7.62 x 10<sup>-6</sup>) and downregulation of *CTNNB1* 

in Mid BMI individuals is associated with the presence of left leg pain (Mid-Stomach-CTNNB1, p=1.93 x

- 350 10<sup>-5</sup>) (**Figure 4, Table S10**). Repeating this analysis according to BMI category reveals a very large
- number of associations specific to the Low BMI category (Figure 4, Table S10); in particular, we note 129
- 352 gene-tissue associations with presence of foot pain, nine of which pass phenotype-wide significance,
- 353 which may indicate a propensity to excess exercise, or exercise-related injuries among these individuals.
- 354

#### 355 Upregulation of CLIC1 is associated with glucagon medication

AN-GReX PheWAS with medication phenotypes was associated with glucagon, a hormone used to treat severe hypoglycemia, in the overall Bio $Me^{TM}$  cohort. Upregulation of *CLIC1* was associated with glucagon in the overall cohort (Spleen-*CLIC1*, p=4.20 x 10<sup>-9</sup>) and also in individuals with Mid BMI (Mid-Spleen-*CLIC1*, p=2.09 x 10<sup>-6</sup>) (**Figure S9, Table S11**).

360

#### 361 Identifying potential case contamination effects

Our Bio*Me*<sup>™</sup> patients have not all been explicitly assessed for eating disorders (ED), and information regarding ED diagnoses and assessments earlier in life may be omitted from the records due to incomplete clinical history assessments. Therefore, it is possible that diagnostic contamination within some of our sample is responsible for the associations observed within our data. In order to test this, we performed a simple experiment.

368 For this simple experiment, we assume that diagnostic contamination occurs among true cases only, at 369 prevalence p. In this case, we expect gene expression among those individuals to be up- or down-370 regulated by effect size beta; consequently, we expect a gene expression difference between cases and 371 controls proportional to the prevalence of the contamination within the sample (p) and the effect size 372 (beta); (Supplementary information). We tested whether such contamination may drive the associations 373 observed in our study, assuming the following different contamination scenarios (Table S12), for two 374 genes with large S-PrediXcan effect sizes: (i) that contamination occurs among cases, assuming the 375 highest common estimate for AN prevalence (0.9% among women, 0.3% among men); (ii) that 376 contamination occurs within our biobank, assuming the highest common estimate for AN prevalence 377 (0.6%, 190 cases), and that all of these samples fall into our 'case' category. 378 379 Our model indicates that diagnostic contamination among cases is unlikely to result in significant 380 PheWAS associations in our data. Contamination occurring at population ED prevalence (0.6%) did not 381 result in significant associations for any of the case-control scenarios in our model (Table S12); nor did 382 contamination at 1.2% or 3%. Assuming 6% contamination resulted in potentially significant associations 383 (estimated p<2.8x10<sup>-8</sup>; see **Methods** and **Supplementary Methods** for more detail).

#### 385 **DISCUSSION**

386

#### 387 AN-associated genes are enriched for associations with psychiatric, autoimmune, and

#### 388 anthropometric phenotypes.

389 Our S-PrediXcan gene results illustrate the contribution of genes associated with metabolic,

anthropometric, autoimmune, and psychiatric phenotypes to AN, and 53% of our genes (25/47) overlap

391 with those from a previous prediXcan analysis of AN cohorts(9). 24/47 AN genes (51%) had variants that

392 were previously associated with some autoimmune disorder in GWAS studies (**Table S5**). The

393 experiment-wide significant loci on chromosome 3 overlaps with a known GWAS peak for inflammatory

bowel disease(44) (IBD), and many of the genes within that peak that we found associated with AN were

also associated with disorders under the IBD umbrella such as Crohn's and ulcerative colitis (Table S5),

396 demonstrating further shared genetic architecture of AN with autoimmune and autoinflammatory

disease(7,8,45,46). Earlier AN GWAS studies have found AN risk loci that overlap with loci implicated in

398 autoimmune disease(47), but the association of *CLIC1* gene expression in tibial nerve that we have found

is the first known association of AN with the MHC locus, a region that has been associated with many

400 other psychiatric disorders(48,49) as well as autoimmune disorders. In particular, *CLIC1* has previously

401 been identified as associated with schizophrenia(50), autism(50), major depressive disorder(51), post-

402 traumatic stress disorder(52), neuroticism(53) and depressive phenotypes(53). Importantly, *CLIC1* 

403 variants have also been associated with complement component C4 and C3 protein levels in the

404 blood(54). C4 is a gene with two isotypes, C4A and C4B, that, through various structural allelic

405 combinations, give rise to complement component 4, which, along with complement component 3 (C3), is

406 part of the complement cascade of proteins(55). Previous research has shown that the complement

407 cascade is involved in not only immunological functions of pathogen clearance (e.g., tagging pathogens

408 for destruction), but also in synaptic pruning and neuronal connectivity(56). The C4A isotype has been

409 associated with schizophrenia risk(55), and both C4A and C4B genes had subthreshold associations with

410 AN in our dataset.

412 CLIC1 (Chloride Intracellular 1) encodes a chloride ion channel protein involved in many necessary 413 cellular functions including the regulation of cell membrane potential, and the proliferation and 414 differentiation of cells(57), including a role in axonal outgrowth of neurons<sup>51</sup>. In addition to neurons, 415 CLIC1 has been found to be expressed in many different tissue types(59), and in particular, CLIC1 416 protein has been found to accumulate in peripheral blood mononuclear cells (PBMCs) when the central 417 nervous system is in a state of chronic inflammation(58), and increased CLIC1 expression has been 418 shown to occur in microglia stimulated by the presence of  $\beta$ -amyloid *in vitro*(60,61). Therefore, CLIC1 419 may potentially act as a biomarker for neurodegenerative disorders such as Alzheimer's disease, and 420 downregulation of CLIC1 has been shown to have a neuroprotective effect in the presence of  $\beta$ -amyloid 421 proteins(58,60–62). Variants in CLIC1 may contribute to risk of multiple psychiatric disorders and 422 behaviors, such as schizophrenia, MDD and PTSD, as well as many autoimmune and immune-related 423 phenotypes such as asthma and systemic lupus erythematosus(50-53)<sup>(63)</sup> (Table S5). Many studies 424 have posed the role of inflammation in the development of psychiatric disorders, and in the etiology of 425 AN(7,8,45,46,64).

426

427 Multiple genes (8/47 or 17%) in our results were associated with regular gym attendance (Table S5), or 428 measures of physical activity. Excessive and compulsive exercise is a behavior often seen in individuals 429 with AN(65,66), and evidence is suggestive that hyperactivity increases risk of chronic AN(67,68). 430 Likewise, genetic studies have shown a strong genetic correlation between AN and physical activity 431  $(r_{a}=0.17)(9.23,69)$ . These genes may reflect a genetic liability to compulsive behaviors of physical activity. 432 Our pain location results point to possible symptoms of excessive activity, with the strong association of 433 AN-GReX with foot pain in Low BMI individuals. Given the known association of AN disease with low 434 bone mineral density (BMD) and propensity for bone fracture(70), our results may reflect the result of 435 genes associated with compulsive exercise and BMD contributing to increased osteoarticular pain. We 436 also see multiple genes that have been previously associated with decreased sleep and insomnia 437 phenotypes (including a core circadian clock gene ARNTL), which have previously been implicated in a 438 range of psychiatric disorders(71-82), including eating disorders(83), as well as in satiety and 439 hunger(84,85).

440

# In a patient population, expression of AN genes is associated with psychiatric, metabolic, and autoimmune phenotypes

443 Unlike GWAS, which include carefully constructed case-control cohorts, PheWAS encompass all 444 individuals within a given healthcare system, including patients with subthreshold or partial presentations 445 of a disorder, or individuals with commonly comorbid or co-diagnosed conditions. Importantly, because 446 individuals enrolled in the biobank are not ascertained for any specific disorder, they likely represent a 447 comprehensive clinical picture of the comorbidities and symptomatology associated with AN gene 448 expression. Examining the consequences of aberrant predicted gene expression among these patients 449 (i.e., testing for GReX-associations) may reveal clinical and biological consequences of these genes; for 450 example, studying whether AN-associated genes have anthropometric and metabolic consequences 451 among adults with no evidence for previous AN- or ED-diagnoses may disentangle whether certain 452 endophenotypes present as a cause, or consequence of AN. For example, it has been postulated that 453 behaviors of food avoidance and restriction may arise due to gastrointestinal complaints and distress that 454 provoke these behaviors and precede development of AN(86). Likewise, autoimmune disorders of the 455 gastrointestinal tract, such as celiac disease and Crohn's disease, show a bidirectional relationship with 456 AN, with previous diagnosis of a GI-associated autoimmune disorders increasing the risk of AN and vice 457 versa(8). Our pheWAS results of AN-GReX associations with gastrointestinal symptoms such as 458 abdominal pain, ascites, and peptic ulcer, as well as GI-related autoimmune disorders like celiac disease, 459 suggest AN-GReX may contribute directly to these diseases and phenotypes, and that food aversive 460 behaviors and gastric distress may be genetically regulated in these individuals, rather than occurring as 461 a consequence of AN. While these associations could be the consequence of undiagnosed AN 462 individuals in our biobank, they more likely reflect real biological associations of expression of those 463 particular genes with the phenotype.

464

465 Our results further confirm the contribution of metabolic factors to AN etiology as we see a very robust
466 association of AN-GReX with type 1 diabetes, and our top findings for AN-GReX with medication
467 prescriptions include the hyperglycemic hormone glucagon and various forms of insulin. The association

468 of AN with metabolic traits and abnormalities has been fairly well established. The Anorexia Nervosa 469 Genetics Initiative reported significant negative genetic correlation between AN and a number of 470 metabolic traits including insulin resistance ( $r_q$ =-0.29), fasting insulin ( $r_q$ =-0.24), leptin ( $r_q$ =-0.26) and type 471 2 diabetes ( $r_0$ =-0.22), and a strong positive genetic correlation with HDL cholesterol ( $r_0$ =0.21)(9). 472 Additional studies have shown associations of AN with fasting insulin(87) and insulin sensitivity(88). 473 Notably, our results point to a similar role of aberrant glycemic regulation in the etiology of AN. Future 474 analyses including EHR-derived lab results (LabWAS) studies may further elucidate AN genes associated 475 with abnormal metabolic regulation and clinical features.

476

#### 477 BMI modification of AN-GReX on clinical outcomes

478 We stratified our pheWAS analyses by BMI in order to observe whether the effects of predicted AN gene 479 expression on clinical outcomes were modified by BMI status, and whether this modification had a 480 significant impact on clinical phenotypes. Specifically, are the AN-GReX-phenotype associations that we 481 see in individuals of High and Low BMI still present when BMI is within the normal "healthy" range? 482 Understanding how BMI is influencing the association of AN-GReX with the clinical phenome might give 483 us further insight into the biological pathways leading to those outcomes and the conferral of AN disease 484 risk. Additionally, we want to understand how BMI could be interacting with AN genetic risk to influence 485 clinical outcomes. We know from our S-PrediXcan analyses and previous GWAS that many genes found 486 to be associated with AN have variants that have been associated with BMI and other anthropometric 487 traits (Table S5). 20/47 AN-genes (42.6%) had evidence from previous GWAS of association with 488 anthropometric measures such as BMI, body fat distribution, waist-to-hip ratio, fat-free mass, obesity, and 489 hip circumference. BMI polygenic risk scores (PRS) have been shown to be associated with disordered 490 eating, with high BMI PRS negatively associated with thin ideal internalization and external eating, where 491 individuals tend to eat in response to external cues of the sight or smell of food(89,90).

492

We postulate that the modification of AN-GReX-weight associations by BMI could be due to actual
biological differences in the regulation of AN gene expression and downstream processes in the presence
of different measures of BMI. CLIC1 is involved in pathways of inflammation, and individuals with a higher

BMI have been shown to have increased systemic inflammation(91), especially in adipose tissues, so it is possible that the modification effect by BMI on the effect of *CLIC1*-GReX on weight measures is happening via a tissue-specific inflammatory process. If we view AN and obesity as metabolic disorders on opposite ends of the spectrum, then perhaps the interaction of BMI with risk for either disorder may lead to differences in metabolic regulation resulting in higher weight phenotypes for those with increased obesity risk, and lower weight phenotypes in those with higher AN risk.

502

Although the hypothesis-free, phenome-wide design of our study allows for powerful detection of clinical and biological consequences of AN risk genes, the same design also bears some notable limitations and caveats. One key caveat to our results is the lack of diagnostic detail and insights available for the patients in our study. EHR analyses leverage large, existing data sets to rapidly amass cohorts for analysis, and to yield insights into whole phenome consequences of genotype and GReX associations; however, the scale and scope of these studies precludes deep phenotyping or performing clinical interviews. This lack of diagnostic precision may arise from a number of factors.

510

511 First, we make use of ICD codes within the medical record in order to infer diagnoses; since these are 512 primarily used by clinicians for billing purposes, they likely provide an imperfect proxy for true disease 513 state. In order to mitigate spurious results stemming from imperfectly assigned codes, we established 514 criteria for inclusion of diagnoses in our analyses: First, diagnosis codes with fewer than 10 counts in the 515 biobank were removed. Second, we only included diagnoses in our pheWAS with at least 10 counts of a 516 code in the ancestral population (i.e., ancestral groups with fewer than 10 case counts were not included 517 in the analysis for that diagnosis), and with a total effective sample size after meta-analysis that was 518 greater than 100. Lastly, within each pheWAS, individuals had to have two or more counts of a diagnosis 519 code to count as a "case", whereas individuals with only one count of a diagnosis code were set to 520 "missing" and not included in the analysis.

521

522 Second, it is possible that our patients regularly receive treatment at multiple different hospital systems;
523 as such, we may be capturing only partial data for each of our patients. In order to mitigate this, we

restricted our analysis to patients with multiple data points within our EHR. Future analyses that seek to harmonize or meta-analyze patient data across EHR (e.g., NYC-CDRN, PsycheMERGE) are ongoing, and will be vital to disentangling this effect further.

527

528 Importantly, our patients have not all been explicitly assessed for EDs, and information regarding ED 529 diagnoses and assessments earlier in life may be omitted from the records due to incomplete clinical 530 history assessments. Therefore, it is possible that case-contamination within some of our sample is 531 responsible for the associations observed within our data. In order to address this, we performed a simple 532 experiment to simulate the effect sizes expected if undiagnosed AN contamination drives our result. We 533 estimated the expected association statistics observed due to two possible levels of contamination among 534 PheWAS cases; i, that 0.06% of PheWAS-trait cases are missing a true AN diagnosis- i.e., the proportion 535 of individuals we expect to receive an AN diagnosis based on standard prevalence estimates; ii, that 536 1.2%, 3% and 6% of individuals in BioMe are missing an AN diagnosis (i.e., double, five times, and ten 537 times the expected population rate), and that all of these individuals fall within our PheWAS trait case 538 group, and applied this model for two genes with large S-PrediXcan effect sizes (NCKIPSD-Aorta; 539 SEMA3F-Spinal Cord). Our model indicates that diagnostic contamination at 0.06%, 1.2% or 3% is 540 insufficient to account for the effect sizes observed within our PheWAS analysis. Moreover, since these 541 genes are selected due to their large S-PrediXcan effect sizes, we expect that the contamination effects 542 observed for these two genes will be greater than any others in our study; as such, we do not believe that 543 our findings are attributable to hidden case contamination. Contamination at 6% resulted in significant 544 differences; however, since this estimate represents a >five-fold increase in expected numbers of AN 545 within a population, we do not expect that this level of contamination occurs in our sample.

546

547 Our results demonstrate that there are real clinical consequences to differences in AN gene expression. 548 Characterization of the phenotypic consequences of AN gene expression in a clinical setting can give us 549 more insight into the biological mechanisms underlying AN and, consequently, how to diagnose and treat 550 the disorder. By understanding the associations of AN gene expression with symptomatology, prodromal 551 or subthreshold disease states, we may gain insights into the biology of the disease, and perhaps identify

- therapeutic targets and opportunities for clinical interventions. For example, if gastrointestinal complaints
- are truly the consequence of aberrant AN gene expression, and contribute to disordered eating due to
- gastrointestinal distress, treatment of those symptoms may help alleviate other AN symptoms or prevent
- 555 development of later AN(92,93). An understanding of the clinical consequences of AN gene expression
- 556 can further augment the definition of AN, and could allow clinicians to more broadly identify individuals at
- 557 greater risk of AN, or those who present with symptom constellations that do not yet meet the established
- 558 diagnostic threshold.

## 559 Acknowledgements

- 560 We are deeply grateful for the mentorship of Pamela Sklar, whose guidance and wisdom we miss daily.
- 561 We strive to continue her legacy of thoughtful, innovative, and collaborative science.
- 562
- 563 JJ and LMH were supported by funding from the Klarman Family Foundation (2019 Eating Disorders
- 564 Research Grants Program) and the NIMH (R01MH118278). CMB is supported by NIMH (R01MH120170;
- 565 R01MH119084; R01MH118278; U01 MH109528); Brain and Behavior Research Foundation
- 566 Distinguished Investigator Grant; Swedish Research Council (Vetenskapsrådet, award: 538-2013-8864);
- 567 Lundbeck Foundation (Grant no. R276-2018-4581).
- 568
- 569 This work was supported in part through the resources and staff expertise provided by the Charles
- 570 Bronfman Institute for Personalized Medicine and The Bio*Me*<sup>™</sup> Biobank Program at the Icahn School of
- 571 Medicine at Mount Sinai.
- 572
- 573 Research reported in this paper was supported by the Office of Research Infrastructure of the National
- 574 Institutes of Health under award numbers S10OD018522 and S10OD026880. The content is solely the
- 575 responsibility of the authors and does not necessarily represent the official views of the National Institutes576 of Health.
- 577

## 578 **Competing Interests**

579 CMB reports: Shire (grant recipient, Scientific Advisory Board member); Idorsia (consultant);

580 Pearson (author, royalty recipient). ML declares that over the past 36 months, he has received lecture

- 581 honoraria from Lundbeck pharmaceutical (No other equity ownership, profit-sharing agreements,
- 582 royalties, or patent). The remaining authors declare no competing interests.

583

#### 585 **REFERENCES**:

- 587 1. Zipfel S, Giel KE, Bulik CM, Hay P, Schmidt U. Anorexia nervosa: aetiology, assessment, and 588 treatment. Lancet Psychiatry. 2015 Dec;2(12):1099–111.
- Bulik CM, Flatt R, Abbaspour A, Carroll I. Reconceptualizing anorexia nervosa. Psychiatry Clin Neurosci. 2019;73(9):518–25.
- 3. Mitchell JE, Peterson CB. Anorexia Nervosa. N Engl J Med. 2020 02;382(14):1343–51.
- 4. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a
   meta-review. World Psychiatry Off J World Psychiatr Assoc WPA. 2014 Jun;13(2):153–60.
- 5. Ulfvebrand S, Birgegård A, Norring C, Högdahl L, von Hausswolff-Juhlin Y. Psychiatric comorbidity in
   women and men with eating disorders results from a large clinical database. Psychiatry Res. 2015
   Dec 15;230(2):294–9.
- 6. Root TL, Pinheiro AP, Thornton L, Strober M, Fernandez-Aranda F, Brandt H, et al. Substance use
   disorders in women with anorexia nervosa. Int J Eat Disord. 2010 Jan;43(1):14–21.
- 599 7. Raevuori A, Haukka J, Vaarala O, Suvisaari JM, Gissler M, Grainger M, et al. The increased risk for autoimmune diseases in patients with eating disorders. PloS One. 2014;9(8):e104845.
- 8. Hedman A, Breithaupt L, Hübel C, Thornton LM, Tillander A, Norring C, et al. Bidirectional relationship
  between eating disorders and autoimmune diseases. J Child Psychol Psychiatry. 2019;60(7):803–
  12.
- 604
  9. Anorexia Nervosa Genetics Initiative, Eating Disorders Working Group of the Psychiatric Genomics
  605
  606
  607
  9. Anorexia Nervosa Genetics Initiative, Eating Disorders Working Group of the Psychiatric Genomics
  605
  606
  607
  607
  9. Anorexia Nervosa Genetics Initiative, Eating Disorders Working Group of the Psychiatric Genomics
  608
  609
  609
  609
  609
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600
  600</li
- Yilmaz Z, Hardaway JA, Bulik CM. Genetics and Epigenetics of Eating Disorders. Adv Genomics
   Genet. 2015;5:131–50.
- Levinson CA, Zerwas SC, Brosof LC, Thornton LM, Strober M, Pivarunas B, et al. Associations
   between dimensions of anorexia nervosa and obsessive-compulsive disorder: An examination of
   personality and psychological factors in patients with anorexia nervosa. Eur Eat Disord Rev J Eat
   Disord Assoc. 2019;27(2):161–72.
- Kaye WH, Wierenga CE, Bailer UF, Simmons AN, Bischoff-Grethe A. Nothing tastes as good as
   skinny feels: the neurobiology of anorexia nervosa. Trends Neurosci. 2013 Feb 1;36(2):110–20.
- Speakman JR, Levitsky DA, Allison DB, Bray MS, Castro JM de, Clegg DJ, et al. Set points, settling
  points and some alternative models: theoretical options to understand how genes and environments
  combine to regulate body adiposity. Dis Model Mech. 2011 Nov 1;4(6):733–45.
- Müller MJ, Bosy-Westphal A, Heymsfield SB. Is there evidence for a set point that regulates human body weight? F1000 Med Rep [Internet]. 2010 Aug 9 [cited 2020 Oct 20];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990627/
- Hebebrand J, Muller TD, Holtkamp K, Herpertz-Dahlmann B. The role of leptin in anorexia nervosa:
   clinical implications. Mol Psychiatry. 2007 Jan;12(1):23–35.

- Hübel C, Yilmaz Z, Schaumberg KE, Breithaupt L, Hunjan A, Horne E, et al. Body composition in anorexia nervosa: Meta-analysis and meta-regression of cross-sectional and longitudinal studies. Int J Eat Disord. 2019;52(11):1205–23.
- Igudesman D, Sweeney M, Carroll IM, Mayer-Davis EJ, Bulik CM. Gut-Brain Interactions:
  Implications for a Role of the Gut Microbiota in the Treatment and Prognosis of Anorexia Nervosa and Comparison to Type I Diabetes. Gastroenterol Clin North Am. 2019;48(3):343–56.
- Huckins LM, Hatzikotoulas K, Southam L, Thornton LM, Steinberg J, Aguilera-Mckay F, et al.
   Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol
   Psychiatry. 2018;23(5).
- Huckins LM, Dobbyn A, McFadden W, Ruderfer D, Wang W, Gamazon E, et al. Identifying tissues
   implicated in Anorexia Nervosa using Transcriptomic Imputation. bioRxiv. 2018;265017.
- 635 20. Hinney A, Kesselmeier M, Jall S, Volckmar A-L, Föcker M, Antel J, et al. Evidence for three genetic
  636 loci involved in both anorexia nervosa risk and variation of body mass index. Mol Psychiatry.
  637 2017;22(2).
- buncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, et al. Significant Locus and
   Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa.
   Am J Psychiatry. 2017 01;174(9):850–8.
- 641 22. Munn-Chernoff MA, Johnson EC, Chou Y-L, Coleman JRI, Thornton LM, Walters RK, et al. Shared
  642 genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from
  643 genome-wide association studies. Addict Biol. 2020 Feb 16;e12880.
- 644 23. Hübel C, Gaspar HA, Coleman JRI, Finucane H, Purves KL, Hanscombe KB, et al. Genomics of
  645 body fat percentage may contribute to sex bias in anorexia nervosa. Am J Med Genet Part B
  646 Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2019;180(6):428–38.
- 647 24. C H, M A, M H, Rj L, G B, Cm B, et al. Binge-eating disorder, anorexia nervosa, and constitutional thinness differ in their associations with anthropometric and psychiatric polygenic scores. 2020 Mar 26 [cited 2020 Aug 20]; Available from: https://europepmc.org/article/ppr/ppr126993
- Smoller JW. The use of electronic health records for psychiatric phenotyping and genomics. Am J
   Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2018;177(7):601–12.
- 652 26. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS:
  653 demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations.
  654 Bioinforma Oxf Engl. 2010 May;26(9):1205–10.
- Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery CL, et al. The use
   of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype
   relationships and pleiotropy discovery. Genet Epidemiol. 2011 Jul;35(5):410–22.
- 28. Zheutlin AB, Dennis J, Karlsson Linnér R, Moscati A, Restrepo N, Straub P, et al. Penetrance and
  Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care
  Systems. Am J Psychiatry. 2019 Aug 16;176(10):846–55.
- Leppert B, Millard LAC, Riglin L, Davey Smith G, Thapar A, Tilling K, et al. A cross-disorder PRS pheWAS of 5 major psychiatric disorders in UK Biobank. PLoS Genet. 2020 May;16(5):e1008185.

- 30. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison
  of phenome-wide association study of electronic medical record data and genome-wide
  association study data. Nat Biotechnol. 2013 Dec;31(12):1102–10.
- Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue
  Expression (GTEx) project. Nat Genet. 2013 Jun;45(6):580–5.
- Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofman L, Wang Y-C, et al. CommonMind
   Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder.
   Sci Data. 2019 Sep 24;6(1):180.
- Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the
  genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res.
  2014 Jan;24(1):14–24.
- 674 34. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene675 based association method for mapping traits using reference transcriptome data. Nat Genet. 2015
  676 Sep;47(9):1091–8.
- Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, et al. Exploring the
   phenotypic consequences of tissue specific gene expression variation inferred from GWAS
   summary statistics. Nat Commun. 2018 May 8;9(1):1825.
- 480 36. Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, et al. Gene expression
  imputation across multiple brain regions provides insights into schizophrenia risk. Nat Genet.
  2019;51(4):659–74.
- Burcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for
  whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007
  Sep;81(3):559–75.
- 686 38. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising
   687 to the challenge of larger and richer datasets. GigaScience. 2015;4:7.
- Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene
  expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci.
  2016;19(11):1442–53.
- 691 40. PheWAS/PheWAS [Internet]. PheWAS; 2019 [cited 2019 Nov 26]. Available from:
   692 https://github.com/PheWAS/PheWAS
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
   scans. Bioinformatics. 2010 Sep 1;26(17):2190–1.
- 42. Verma A, Bradford Y, Dudek S, Lucas AM, Verma SS, Pendergrass SA, et al. A simulation study
  investigating power estimates in phenome-wide association studies. BMC Bioinformatics. 2018 Apr
  4;19(1):120.
- Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. Developing and Evaluating Mappings of
   ICD-10 and ICD-10-CM Codes to PheCodes. bioRxiv. 2019 Jul 3;462077.
- 44. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide
   association study implicates immune activation of multiple integrin genes in inflammatory bowel
   disease. Nat Genet. 2017 Feb;49(2):256–61.

- Mårild K, Størdal K, Bulik CM, Rewers M, Ekbom A, Liu E, et al. Celiac Disease and Anorexia
   Nervosa: A Nationwide Study. Pediatrics. 2017 May;139(5).
- S Z, Jt L, L P, Lm T, M Q, Sv K, et al. Eating Disorders, Autoimmune, and Autoinflammatory
  Disease. Pediatrics [Internet]. 2017 Nov 9 [cited 2020 Nov 16];140(6). Available from:
  https://europepmc.org/article/med/29122972
- 47. Gibson D, Mehler PS. Anorexia Nervosa and the Immune System—A Narrative Review. J Clin Med.
   2019 Nov;8(11):1915.
- 48. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide
  association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019 May;51(5):793.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108
   schizophrenia-associated genetic loci. Nature. 2014 Jul;511(7510):421–7.
- The Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium. Metaanalysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Mol Autism. 2017 Dec;8(1):21.
- 51. Zhu Z, Zhu X, Liu C-L, Shi H, Shen S, Yang Y, et al. Shared genetics of asthma and mental health
  disorders: a large-scale genome-wide cross-trait analysis. Eur Respir J [Internet]. 2019 Dec 1 [cited
  2020 May 21];54(6). Available from: https://erj.ersjournals.com/content/54/6/1901507-0
- 52. Marchese S, Hoffman G, Pietrzak RH, Lebovitch D, Daskalakis NP, Yehuda R, et al. Altered gene expression and PTSD symptom dimensions in World Trade Center responders. In Prep. 2020;
- 53. Baselmans BML, Jansen R, Ip HF, van Dongen J, Abdellaoui A, van de Weijer MP, et al.
  Multivariate Genome-wide and integrated transcriptome and epigenome-wide analyses of the Wellbeing spectrum [Internet]. Genetics; 2017 Mar [cited 2020 May 21]. Available from: http://biorxiv.org/lookup/doi/10.1101/115915
- 54. Yang X, Sun J, Gao Y, Tan A, Zhang H, Hu Y, et al. Genome-Wide Association Study for Serum
  Complement C3 and C4 Levels in Healthy Chinese Subjects. PLOS Genet. 2012 Sep
  13;8(9):e1002916.
- 55. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83.
- 56. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.
- 57. Li B, Mao Y, Wang Z, Chen Y, Wang Y, Zhai C, et al. CLIC1 Promotes the Progression of Gastric
  Cancer by Regulating the MAPK/AKT Pathways. Cell Physiol Biochem. 2018;46(3):907–24.
- 58. Carlini V, Verduci I, Cianci F, Cannavale G, Fenoglio C, Galimberti D, et al. CLIC1 Protein
   Accumulates in Circulating Monocyte Membrane during Neurodegeneration. Int J Mol Sci. 2020
   Jan;21(4):1484.
- Facal F, Costas J. Evidence of association of the DISC1 interactome gene set with schizophrenia
   from GWAS. Prog Neuropsychopharmacol Biol Psychiatry. 2019 20;95:109729.

Milton RH, Abeti R, Averaimo S, DeBiasi S, Vitellaro L, Jiang L, et al. CLIC1 function is required for
 beta-amyloid-induced generation of reactive oxygen species by microglia. J Neurosci Off J Soc
 Neurosci. 2008 Nov 5;28(45):11488–99.

- Novarino G, Fabrizi C, Tonini R, Denti MA, Malchiodi-Albedi F, Lauro GM, et al. Involvement of the
  intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J
  Neurosci Off J Soc Neurosci. 2004 Jun 9;24(23):5322–30.
- Swarup V, Chang TS, Duong DM, Dammer EB, Dai J, Lah JJ, et al. Identification of Conserved
   Proteomic Networks in Neurodegenerative Dementia. Cell Rep. 2020 Jun 23;31(12):107807.
- Lee YH, Bae S-C, Choi SJ, Ji JD, Song GG. Genome-wide pathway analysis of genome-wide
  association studies on systemic lupus erythematosus and rheumatoid arthritis. Mol Biol Rep. 2012
  Dec 1;39(12):10627–35.
- 75164.Nilsson IAK, Millischer V, Göteson A, Hübel C, Thornton LM, Bulik CM, et al. Aberrant inflammatory752profile in acute but not recovered anorexia nervosa. Brain Behav Immun. 2020 Aug 1;88:718–24.
- Bulik CM. Genetic and Biological Risk Factors. In: Thompson JK, editor. Handbook of Eating
  Disorders and Obesity [Internet]. Hoboken, NJ: Wiley; 2004. p. 3. Available from: https://books.google.com/books/about/Handbook%7B\_%7Dof%7B\_%7DEating%7B\_%7DDisorders
  %7B\_%7Dand%7B\_%7DObesity.html?id=KZhHAAAAMAAJ%7B&%7Dpgis=1
- 66. Shroff H, Reba L, Thornton LM, Tozzi F, Klump KL, Berrettini WH, et al. Features associated with excessive exercise in women with eating disorders. Int J Eat Disord. 2006 Sep;39(6):454–61.
- Achamrah N, Coëffier M, Déchelotte P. Physical activity in patients with anorexia nervosa. Nutr Rev.
   2016 May 1;74(5):301–11.
- Strober M, Freeman R, Morrell W. The long-term course of severe anorexia nervosa in adolescents:
  Survival analysis of recovery, relapse, and outcome predictors over 10–15 years in a prospective
  study. Int J Eat Disord. 1997;22(4):339–60.
- Hübel C, Gaspar HA, Coleman JRI, Hanscombe KB, Purves K, Prokopenko I, et al. Genetic
  correlations of psychiatric traits with body composition and glycemic traits are sex- and agedependent. Nat Commun. 2019 18;10(1):5765.
- 767 70. Solmi M, Veronese N, Correll CU, Favaro A, Santonastaso P, Caregaro L, et al. Bone mineral
   768 density, osteoporosis, and fractures among people with eating disorders: a systematic review and
   769 meta-analysis. Acta Psychiatr Scand. 2016 May;133(5):341–51.
- 770 71. Etain B, Jamain S, Milhiet V, Lajnef M, Boudebesse C, Dumaine A, et al. Association between circadian genes, bipolar disorders and chronotypes. Chronobiol Int. 2014 Aug;31(7):807–14.
- 772 72. Melo MCA, Abreu RLC, Linhares Neto VB, de Bruin PFC, de Bruin VMS. Chronotype and circadian
   773 rhythm in bipolar disorder: A systematic review. Sleep Med Rev. 2017 Aug;34:46–58.
- 774 73. Huckins L, Dobbyn A, McFadden W, Wang W, Ruderfer D, Hoffman G, et al. Transcriptomic
   775 Imputation of Bipolar Disorder and Bipolar subtypes reveals 29 novel associated genes. bioRxiv.
   2017 Nov;222786.
- 777 74. Meyrer R, Demling J, Kornhuber J, Nowak M. Effects of night shifts in bipolar disorders and extreme morningness. Bipolar Disord. 2009 Dec;11(8):897–9.
- Alloy LB, Ng TH, Titone MK, Boland EM. Circadian Rhythm Dysregulation in Bipolar Spectrum
   Disorders. Curr Psychiatry Rep. 2017 Apr;19(4):21.
- 781
   76. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J
   782 Psychiatry Neurosci JPN. 2000 Nov;25(5):446–58.

- 783
   77. Bunney BG, Bunney WE. Mechanisms of Rapid Antidepressant Effects of Sleep Deprivation
   784 Therapy: Clock Genes and Circadian Rhythms. Biol Psychiatry. 2013 Jun;73(12):1164–71.
- 785
   78. Bunney BG, Li JZ, Walsh DM, Stein R, Vawter MP, Cartagena P, et al. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Mol Psychiatry. 2015
   787
   780
   780
   780
   781
   782
   783
   784
   785
   785
- 788
   79. Karatsoreos IN. Links between Circadian Rhythms and Psychiatric Disease. Front Behav Neurosci.
   2014;8:162.
- Kripke DF, Mullaney DJ, Atkinson M, Wolf S. Circadian rhythm disorders in manic-depressives. Biol
   Psychiatry. 1978 Jun;13(3):335–51.
- 81. Mansour HA, Talkowski ME, Wood J, Chowdari KV, McClain L, Prasad K, et al. Association study of
  21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar
  Disord. 2009 Nov;11(7):701–10.
- Murray G, Allen NB, Trinder J, Burgess H. Is weakened circadian rhythmicity a characteristic of neuroticism? J Affect Disord. 2002 Dec;72(3):281–9.
- Allison KC, Spaeth A, Hopkins CM. Sleep and Eating Disorders. Curr Psychiatry Rep.
   2016;18(10):92.
- Arble DM, Bass J, Laposky AD, Vitaterna MH, Turek FW. Circadian timing of food intake contributes
   to weight gain. Obesity. 2009;17(11):2100–2.
- 801
   85. Herpertz S, Albers N, Wagner R, Pelz B, Köpp W, Mann K, et al. Longitudinal changes of circadian
   802
   803
   804
   805
   805
   806
   806
   807
   807
   808
   808
   809
   809
   809
   809
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   800
   <l
- 804 86. Zucker NL, Bulik CM. On bells, saliva, and abdominal pain or discomfort: Early aversive visceral conditioning and vulnerability for anorexia nervosa. Int J Eat Disord. 2020;53(4):508–12.
- 806
   87. Adams DM, Reay WR, Geaghan MP, Cairns MJ. Investigation of glycaemic traits in psychiatric disorders using Mendelian randomisation revealed a causal relationship with anorexia nervosa. Neuropsychopharmacology. 2020 Sep 13;1–10.
- 809
   88. Ilyas A, Hübel C, Stahl D, Stadler M, Ismail K, Breen G, et al. The metabolic underpinning of eating disorders: A systematic review and meta-analysis of insulin sensitivity. Mol Cell Endocrinol. 2019
   811
   Nov 1;497:110307.
- 812 89. Abdulkadir M, Herle M, De Stavola BL, Hübel C, Santos Ferreira DL, Loos RJF, et al. Polygenic
  813 Score for Body Mass Index Is Associated with Disordered Eating in a General Population Cohort. J
  814 Clin Med [Internet]. 2020 Apr 21 [cited 2020 Nov 3];9(4). Available from:
  815 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231239/
- 816 90. Nagata JM, Braudt DB, Domingue BW, Bibbins-Domingo K, Garber AK, Griffiths S, et al. Genetic
  817 risk, body mass index, and weight control behaviors: Unlocking the triad. Int J Eat Disord.
  818 2019;52(7):825–33.
- 819 91. Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin
   820 Pharmacol. 2016 Aug 1;29:77–89.

- 821 92. Wiklund CA, Kuja-Halkola R, Thornton LM, Hübel C, Leppä V, Bulik CM. Prolonged constipation and diarrhea in childhood and disordered eating in adolescence. J Psychosom Res. 2019;126:109797.
- 824
  825
  826
  93. Riedlinger C, Schmidt G, Weiland A, Stengel A, Giel KE, Zipfel S, et al. Which Symptoms, Complaints and Complications of the Gastrointestinal Tract Occur in Patients With Eating Disorders? A Systematic Review and Quantitative Analysis. Front Psychiatry. 2020;11:195.





CLIC1-Adipose Subcutaneous

CLIC1-Breast Mammary Tissue



# BMI Group OVERALL HIGH MID LOW

Significant NS



# Diagnosis Group











iii. Mid BMI



Low BMI iv.







# **BioMe BioBank Demographic Information**

		Total N	N Self-report Female (%)	N Self-report Male (%)	Mean Age (1stQ-3rdQ)	Mean BMI (1s
Total Cohort		31585	17968 (57)	12417 (39)	57.12 (45-69)	28.69 (27.46
	AA	8044	4945 (61)	2937 (37)	55.76 (45-66)	30.63 (25.06
	EA	10788	5273 (49)	4766 (44)	58.79 (45-72)	26.58 (22.64
Ancostru	ESA	957	567 (59)	332 (35)	50 (38-60)	24.26 (21.22
Ancestry	HA	11047	6863 (62)	3980 (36)	57.42 (45-70)	29.64 (25.17
	SAS	661	275 (42)	360 (54)	52.93 (39-66)	26.14 (23.04
	NA	88	45 (51)	42 (48)	57.03 (46.5-69)	28.35 (24.24

tQ-3rdQ) -32.09) -34.81) -29.39) -26.21) -32.95) -28.52) -31.43)

## Chromosome

## Genes

medRxiv preprint doi: https://doi.org/10.1101/2021.02.122.1250941; this version posted March 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/uncer, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.		-4.851060	1.23e-06	FBLIM1	Liver
2	ASB3, CHAC2, GPR75		7.46e-09	GPR75	Whole_Blood
3	SPINK8, PFKFB4, TMEM89, SLC26A6, CELSR3, NCKIPSD, ARIH2OS, ARIH2, P4HTM, WDR6, DALRD3, NDUFAF3, USP19, LAMB2, CCDC71, CCDC36, C3orf62, GPX1, NICN1, DAG1, APEH, MST1, MST1R, RNF123, RBM6, RBM5, SEMA3F, TUSC2	7.321127	2.46e-13	WDR6	Skin_Sun_Exposed_Lower_leg
3	PROS1, DHFRL1	4.687382	2.77e-06	DHFRL1	DGN_Whole_Blood
6	CLIC1	4.814629	1.47e-06	CLIC1	Nerve_Tibial
10	MGMT, EBF3	-5.086391	3.65e-07	MGMT	Thyroid
11	ARNTL	4.534957	5.76e-06	ARNTL	Whole_Blood
12	SUOX, RPS26, SLC26A10	4.628307	3.69e-06	RPS26	Uterus
17	TNFSF12, LINC00324	4.982641	6.27e-07	TNFSF12	Breast_Mammary_Tissue
20	SLC2A10	4.921176	8.60e-07	SLC2A10	Nerve_Tibial
22	KREMEN1	4.872670	1.10e-06	KREMEN1	Nerve_Tibial
22	SCO2	-4.560015	5.11e-06	SCO2	Brain_Cerebellum

Zscore	P-value	Top Finding (Gene)	Top Finding (Tissue)
-4.851060	1.23e-06	FBLIM1	Liver
-5.780228	7.46e-09	GPR75	Whole_Blood